SPEAKERS

Session 1

Session 2

Session 3

speaker

Dr. Fernando López-Ríos (Chair)

12 de Octubre University Hospital Spain

See Bio
speaker

Prof. Keith Kerr

South-West Genomic Laboratory Hub, Bristol, UK

See Bio
speaker

Prof. Rachel Butler

South-West Genomic Laboratory Hub, Bristol, UK

See Bio
speaker

Dr. Justin Gainor

Massachusetts General Hospital Harvard Medical School Boston, USA

See Bio
speaker

Prof. Maurice Pérol

Centre Léon Bérard, Lyon, France

See Bio
speaker

Prof. Lecia Sequist

Massachusetts General Hospital Harvard Medical School Boston, USA

See Bio
speaker

Dr. Natasha Leighl

Princess Margaret Cancer Centre, Toronto, Canada

See Bio
speaker

Dr. Alastair Greystoke

Sir Bobby Robson Clinical Trials Unit, Freeman Hospital, Newcastle, UK

See Bio
speaker

Dr. Fernando López-Ríos (Chair)

12 de Octubre University Hospital Spain

See Bio
speaker

Prof. Maurice Pérol

Centre Léon Bérard, Lyon, France

See Bio
speaker

Dr. Alastair Greystoke

Sir Bobby Robson Clinical Trials Unit, Freeman Hospital, Newcastle, UK

See Bio
speaker

Prof. Rachel Butler

South-West Genomic Laboratory Hub, Bristol, UK

See Bio
speaker

Dr. Fernando López-Ríos (Chair)

12 de Octubre University Hospital Spain

See Bio
speaker

Dr. Justin Gainor

Massachusetts General Hospital Harvard Medical School Boston, USA

See Bio
speaker

Prof. Keith Kerr

South-West Genomic Laboratory Hub, Bristol, UK

See Bio
speaker

Dr. Natasha Leighl

Princess Margaret Cancer Centre, Toronto, Canada

See Bio
speaker

Prof. Lecia Sequist

Massachusetts General Hospital Harvard Medical School Boston, USA

See Bio
speaker

Dr. Fernando López-Ríos (Chair)

12 de Octubre University Hospital Spain

See Bio
speaker

Dr. Justin Gainor

Massachusetts General Hospital Harvard Medical School Boston, USA

See Bio
speaker

Prof. Keith Kerr

South-West Genomic Laboratory Hub, Bristol, UK

See Bio
speaker

Dr. Natasha Leighl

Princess Margaret Cancer Centre, Toronto, Canada

See Bio
speaker

Prof. Lecia Sequist

Massachusetts General Hospital Harvard Medical School Boston, USA

See Bio

This exciting event series will include expert
commentary on:

The role of molecular testing

  • • The role of molecular testing in advanced/
    metastatic oncogene-driven NSCLC
  • • Why testing for EGFR, ALK and ROS1 is
    important in NSCLC
  • • Role of Biomarker Testing in treatment
    selection
  • • Current challenges to widespread uptake of
    molecular diagnostics in NSCLC

Best practice approaches to
molecular testing

  • • Tissue biopsy
  • • Approaches to molecular testing
    (sequential vs parallel)
  • • Understanding testing methods

Interpreting results

  • • How to interpret test results
  • • Timelines for test results
  • • Making treatment decisions

Real life case studies

SESSION TIME BY CITY

Session 1 - 21 October 2021
City Time
Madrid 09:00
Dubai 11:00
Singapore 15:00
Sydney 17:00
REGISTER ADD TO CALENDAR
Session 2 - 21 October 2021
City Time
New York 08:00
Rio de Janeiro 09:00
Madrid 14:00
Dubai 16:00
REGISTER ADD TO CALENDAR
Session 3 - 21 October 2021
City Time
New York 13:00
Rio de Janeiro 14:00
Madrid 19:00
Dubai 21:00
REGISTER ADD TO CALENDAR

SCHEDULE

SESSION 1

SESSION 2

SESSION 3

Topic
Speakers
Welcome and Introduction
Chair: Fernando López-Ríos (Spain)
The role of molecular testing in advanced/
metastatic oncogene-driven NSCLC
Maurice Perol (France)
Best practice approaches to molecular testing in
advanced/metastatic oncogene-driven NSCLC
Fernando López-Ríos (Spain)
Molecular testing results
Alastair Greystoke (UK)
Case Study / Real life country experience
Rachel Butler (UK)
Topic
Speakers
Welcome and Introduction
Chair: Fernando López-Ríos (Spain)
The role of molecular testing in advanced/
metastatic oncogene-driven NSCLC
Justin Gainor (US)
Best practice approaches to molecular testing in
advanced/metastatic oncogene-driven NSCLC
Keith Kerr (UK)
Molecular testing results
Lecia Sequist (US)
Case Study / Real life country experience
Natasha Leighl (Canada)
Topic
Speakers
Welcome and Introduction
Chair: Fernando López-Ríos (Spain)
The role of molecular testing in advanced/
metastatic oncogene-driven NSCLC
Justin Gainor (US)
Best practice approaches to molecular testing in
advanced/metastatic oncogene-driven NSCLC
Keith Kerr (UK)
Molecular testing results
Lecia Sequist (US)
Case Study / Real life country experience
Natasha Leighl (Canada)